PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor . PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD). PDC31 also enhances Ca 2+ -dependent large-conductance K + -channel in human myometrial cells In Vitro PDC31 (10 μM, 50 μM; ) stimulates the BK Ca channel in human myometrial smooth muscle cells, and enhances open state channel activity with average 4 and 6-fold by 10 and 50 μM, respectively. PDC31 (1 nM-10 μM; 20 min intervals) cumulatively inhibits spontaneous contractions in isolated pregnant human myometrium. PDC31 consists of ILGHXDYK, associated sequence is based on a transmembrane domain of the human PGF2a receptor. PDC31 has been shown to reduce the duration and strength of PGF2a-induced contractions in myometrial strip models and to delay delivery in animal models of preterm labor . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:FP Receptor ~30 nM (Ki) PGF 2α